ClinicalTrials.gg
Active, not recruitingNCT06969573Updated Nov 5, 2026

Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD

A Phase 2 interventional study of Placebo and Treprostinil Inhalation Solution 36 mcg in COPD (Chronic Obstructive Pulmonary Disease), sponsored by University of Alberta. Active, not recruiting at 1 site in Canada. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by University of Alberta · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Pulmonary Disease, Chronic Obstructive by University of Alberta — 2 open to participants now, 3 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University of Alberta.

Enrollment
11th of 13
20 · median 80
Started
2025
the only one that year
Phase 2
3 of 17
1 open now
Registered
17th of 17
by date

Among the 17 studies in Pulmonary Disease, Chronic Obstructive by University of Alberta, this one is the 11th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 2, and was the 17th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies in Pulmonary Disease, Chronic Obstructive by University of Alberta are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 50 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Pulmonary Disease, Chronic Obstructive by University of Alberta, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Participants will be asked to:

  • Perform lung function and exercise tests
  • Have ultrasound of their heart
  • Have CT images of their lungs
  • Visit the lab on 5 different occasions (plus one visit to the CT imaging clinic)

The researchers will compare the effectiveness and feasibility of inhaled Treprostinil to improve breathlessness upon exertion and exercise capacity

Read the detailed description

The study consists of 6 visits (5 to the Clinical Sciences Building at the University of Alberta):

Day 1: participants will provide informed consent, medical history and health screening (Physical activity readiness questionnaire [PAR-Q+], COPD assessment test [CAT], modified medical research council [mMRC], euro quality of life- 5 dimensions [EQ-5D]), be familiarized to the laboratory and experimental measurement protocols, conduct a pulmonary function test, and conduct an incremental CPET to determine peak oxygen consumption (V̇O2peak) on the cycle ergometer. Throughout exercise, non-invasive measurements of cardiac output (impedance cardiography), heart rate (electrocardiogram), expired gases (metabolic cart), and oxygen saturation (pulse oximetry) will be completed. A small blood sample will be collected via finger prick to measure hemoglobin (to correct DLCO - part of the pulmonary function test). Ratings of perceived breathing and leg discomfort (Borg scale), as well as dimensional descriptors of dyspnea scales will be recorded throughout the exercise test, and immediately upon exercise cessation.

Days 2-4: participants will complete resting, seated, DLCO maneuvers as well as a constant workload (75% of the peak power output determined from the CPET) cycling exercise test until volitional fatigue (i.e., exhaustion) with or without inhaled Treprostinil (placebo, 36, or 78 mcg; via Tyvaso® Inhalation Solution). DLCO and its components will be evaluated by standardized multiple breath-hold technique. A small blood sample will be collected via finger prick to measure hemoglobin for the DLCO maneuvers prior to and following exercise. Throughout exercise, non-invasive measurements of cardiac output (impedance cardiography), heart rate (electrocardiogram), expired gases (metabolic cart), and oxygen saturation (pulse oximetry) will be completed. Additionally, ratings of perceived breathing and leg discomfort (Borg scale), as well as dimensional descriptors of dyspnea scales will be recorded throughout the exercise test, and immediately upon exercise cessation. The drug condition (placebo, 36, or 78 mcg) will be randomized (block randomization) by a member of our research team who is not involved in data analysis or collection.

Day 5: participants will complete supine DLCO maneuvers (multiple breath-hold technique) as well as resting echocardiography (to measure pulmonary artery and cardiac function) with and without inhaled Treprostinil (placebo, 36, and 78 mcg). A small blood sample will be collected via finger prick to measure hemoglobin for the DLCO maneuvers.

Day 6: participants will undergo a low contrast CT scan of their chest for quantification of pulmonary vascular volumes (i.e., blood vessel volume in the lungs). No drug intervention will be completed on Day 6.

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)

Keywords

  • dyspnea
  • exercise tolerance
  • exercise capacity
  • inhaled Treprostinil
  • Prostacyclin
  • pulmonary vascular
04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with mild (defined as having a postbronchodilator /FVC ratio \<0.70 and FEV1 ≥ 80% predicted

Exclusion criteria

Exclusion Criteria:

  • Pre-existing heart failure and pulmonary artery hypertension.
  • Known thrombocytopenia.
  • Resting blood pressure of \<90mmHg systolic and \<50 mmHg diastolic.
  • Known sensitivity to prostanoids
  • Severe hepatic insufficiency
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will inhale placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer

    Drug: Placebo

  • Experimental
    Treprostinil 36 mcg

    Participants will inhale 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

    Combination Product: Treprostinil Inhalation Solution 36 mcg

  • Experimental
    Treprostinil 78 mcg

    Participants will inhale 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

    Combination Product: Treprostinil Inhalation Solution 78 mcg

Interventions

  • DrugPlacebo

    Participants will breathe placebo (room air) from the Tyvaso Inhalation System Ultrasonic nebulizer

  • Combination productTreprostinil Inhalation Solution 36 mcg

    Participants will breathe either 36 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

  • Combination productTreprostinil Inhalation Solution 78 mcg

    Participants will breathe either 78 mcg of Treprostinil from the Tyvaso Inhalation System Ultrasonic nebulizer

06

What researchers measure

Primary outcomes

  1. Exercise tolerance

    Time to symptom limitation/exhaustion during a constant work rate test.

    Time frame: Within 30-45 minutes post dose

  2. Exertional dyspnea

    Maximal perceived breathing discomfort during exercise

    Time frame: Within 30-45 minutes post dose

  3. Ventilatory efficiency

    Nadir value of the ratio between ventilation and the rate of CO2 production (Ve/VCO2 nadir)

    Time frame: Within 30-45 minutes post dose

Secondary outcomes

  1. Lung diffusing capacity

    Lung diffusing capacity (DLCO) will be measured using six-second, advanced DLCO techniques.

    Time frame: Within 15-30 minutes post dose

  2. Pulmonary capillary blood volume (Vc)

    Pulmonary capillary blood volume (Vc) will be measured using six-second, advanced DLCO techniques.

    Time frame: Within 15-30 minutes post dose

  3. Diffusing membrane Capacity (Dm)

    Diffusing membrane capacity will be measured using six-second, advanced DLCO techniques.

    Time frame: Within 15-30 minutes post dose

  4. Cardiac structure and function

    echocardiography-derived right ventricular systolic pressure

    Time frame: Within 15-30 minutes post dose

  5. Pulmonary vascular volumes

    Chest computed tomography (CT) scan

    Time frame: Day 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 47 non-industry phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 63. This study's planned 18 months is below that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2025
First posted
May 14, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06969573
Responsible party
Sponsor
First posted
May 14, 2025
Start date
Jun 5, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 5, 2026

Study contacts

Michael Stickland
principal investigator · University of Alberta

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion